Emixustat and lampalizumab: Potential therapeutic options for geographic atrophy

Developments in Ophthalmology

Volumn 55, Issue , 2015, Pages 302-309

  Jack, Loren S ^a   Sadiq, Mohammad Ali ^a   Do, Diana V ^a   Nguyen, Quan Dong ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHENYL ETHER DERIVATIVE; EMIXUSTAT; IMMUNOGLOBULIN F(AB) FRAGMENT; LAMPALIZUMAB; PROPANOLAMINE DERIVATIVE;

CLINICAL TRIAL (TOPIC); GEOGRAPHIC ATROPHY; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; CLINICAL TRIALS AS TOPIC; GEOGRAPHIC ATROPHY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INTRAVITREAL INJECTIONS; PHENYL ETHERS; PROPANOLAMINES;

EID: 84947261989     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000438954     Document Type: Article

References (39)

1. Suter M: Age-related macular degeneration. The lipofuscin component N-retinyl-N-retinylidene ethanolamine detaches proapoptotic proteins from mitochondria and incuces apoptosis in mammalian retinal pigment epithelial cells. J Biol Chem 2000; 275:39625-39630.
2. Sparrow JR, Cai B: Blue light-induced apoptosis of A2E-containing RPE: involvement of caspase-3 and protection by Bcl-2. Invest Ophthalmol Vis Sci 2001; 42:1356-1362.
3. Finnemann SC, Leung LW, Rodriguez-Boulan E: The lipofuscin component A2E selectively inhibits phagolysosomal degradation of photoreceptor phospholipid by the retinal pigment epithelium. Proc Natl Acad Sci U S A 2002; 99:3842-3847.
4. Eldred GE: Age pigment structure. Nature 1993; 364:396.
5. Eldred GE, Lasky MR: Retinal age pigments generated by self-Assembling lysosomotropic detergents. Nature 1993; 361:724-726.
6. Sparrow JR, Parish CA, Hashimoto M, Nakanishi K: A2E, a lipofuscin fluorophore, in human retinal pigmented epithelial cells in culture. Invest Ophthalmol Vis Sci 1999; 40:2988-2995.
7. De S, Skamar TP: Interaction of A2E with model membranes. Implications to the pathogenesis of age-related macular degeneration. J Gen Physiol 2002; 120:147-157.
8. Cubeddu R, Taroni P, Hu DN, Sakai N, Nakanishi K, Roberts JE: Photophysical studies of A2-E, putative precursor of lipofuscin, in human retinal pigment epithelial cells. Photochem Photobiol 1999; 70:172-175.
9. Sparrow JR, Nakanishi K, Parish CA: The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells. Invest Ophthalmol Vis Sci 2000; 41:1981-1989.
10. Schütt F, Davies S, Kopitz J, Holz FG, Boulton ME: Photodamage to human RPE cells by A2-E, a retinoid component of lipofuscin. Invest Ophthalmol Vis Sci 2000; 41:2303-2308.
11. Sparrow JR: A2E-epoxides damage DNA in retinal pigment epithelial cells. Vitamin E and other antioxidants inhibit A2E-epoxide formation. J Biol Chem 2003; 278:18207-18213.
12. Sparrow JR, Fishkin N, Zhou J, Cai B, Jang YP, Krane S, et al. A2E, a byproduct of the visual cycle. Vision Res 2003; 43:2983-2990.
13. Holz FG, Schütt F, Kopitz J, Eldred GE, Kruse FE, Völcker HE, et al. Inhibition of lysosomal degradative functions in RPE cells by a retinoid component of lipofuscin. Invest Ophthalmol Vis Sci 1999; 40:737-743.
14. Steinberg RH: Interactions between the retinal pigment epithelium and the neural retina. Doc Ophthalmol Adv Ophthalmol 1985; 60:327-346.
15. Sparrow JR: Bisretinoids of RPE lipofuscin: trigger for complement activation in age-related macular degeneration. Adv Exp Med Biol 2010; 703:63-74.
16. Longbottom R, Fruttiger M, Douglas RH, Martinez-Barbera JP, Greenwood J, Moss SE: Genetic ablation of retinal pigment epithelial cells reveals the adaptive response of the epithelium and impact on photoreceptors. Proc Natl Acad Sci U S A 2009; 106:18728-18733.
17. Delori FC, Dorey CK, Staurenghi G, Arend O, Goger DG, Weiter JJ: In vivo fluorescence of the ocular fundus exhibits retinal pigment epithelium lipofuscin characteristics. Invest Ophthalmol Vis Sci 1995; 36:718-729.
18. Holz FG, Bellman C, Staudt S, Schütt F, Völcker HE: Fundus autofluorescence and development of geographic atrophy in age-related macular degeneration. Invest Ophthalmol Vis Sci 2001; 42:1051-1056.
19. Holz FG, Bindewald-Wittich A, Fleckenstein M, Dreyhaupt J, Scholl HPN, Schmitz-Valckenberg S: Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol 2007; 143:463-472.e2.
20. Schmitz-Valckenberg S: Correlation between the area of increased autofluorescence surrounding geographic atrophy and disease progression in patients with AMD. Invest Ophthalmol Vis Sci 2006; 47:2648-2654.
21. Schmitz-Valckenberg S, Bültmann S, Dreyhaupt J, Bindewald A, Holz FG, Rohrschneider K: Fundus autofluorescence and fundus perimetry in the junctional zone of geographic atrophy in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci 2004; 45:4470-4476.
22. Scholl HP, Bellmann C, Dandekar SS, Bird AC, Fitzke FW: Photopic and scotopic fine matrix mapping of retinal areas of increased fundus autofluorescence in patients with age-related maculopathy. Invest Ophthalmol Vis Sci 2004; 45:574-583.
23. Kubota R, Al-Fayoumi S, Mallikaarjun S, Patil S, Bavik C, Chandler JW: Phase 1, dose-ranging study of emixustat hydrochloride (ACU-4429), a novel visual cycle modulator, in healthy volunteers. Retina 2014; 34:603-609.
24. Kubota R, Boman NL, David R, Mallikaarjun S, Patil S, Birch D: Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator. Retina 2012; 32:183-188.
25. Strauss O: The retinal pigment epithelium in visual function. Physiol Rev 2005; 85:845-881.
26. Marlhens F, Bareil C, Griffoin JM, Zrenner E, Amalric P, Eliaou C, et al. Mutations in RPE65 cause Leber's congenital amaurosis. Nat Genet 1997; 17:139-141.
27. Xu F, Dong Q, Liu L, Li H, Liang X, Jiang R, et al. Novel RPE65 mutations associated with Leber congenital amaurosis in Chinese patients. Mol Vis 2012; 18:744.
28. Verma A, Perumalsamy V, Shetty S, Kulm M, Sundaresan P: Mutational screening of LCA genes emphasizing RPE65 in South Indian cohort of patients. PLoS One 2013; 8:e73172.
29. Bowne SJ, Humphries MM, Sullivan LS, Kenna PF, Tam LC, Kiang AS, et al. A dominant mutation in RPE65 identified by whole-exome sequencing causes retinitis pigmentosa with choroidal involvement. Eur J Hum Genet 2011; 19:1074-1081.
30. Golczak M, Maeda A, Bereta G, Maeda T, Kiser PD, Hunzelmann S, et al. Metabolic basis of visual cycle inhibition by retinoid and nonretinoid compounds in the vertebrate retina. J Biol Chem 2008; 283:9543-9554.
31. Maeda T, Maeda A, Matosky M, Okano K, Roos S, Tang J, et al. Evaluation of potential therapies for a mouse model of human age-related macular degeneration caused by delayed all-Drans-retinal clearance. Invest Ophthalmol Vis Sci 2009; 50:4917-4925.
32. Messias A, Zrenner E, Tzekov R, McGee D, Peters T, Wilhelm B, et al. Single doses of all-Drans-N-retinylacetamide slow down the ERG amplitude recovery after bleaching in rats. Doc Ophthalmol Adv Ophthalmol 2010; 120:165-174.
33. Akula JD, Hansen RM, Tzekov R, Favazza TL, Vyhovsky TC, Benador IY, et al. Visual cycle modulation in neurovascular retinopathy. Exp Eye Res 2010; 91:153-161.
34. Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride (SEATTLE). US National Institutes of Health, 2013, http://clinicaltrials.gov/ct2/show/NCT01802866.
35. Do DV, Pieramici DJ, van Lookeren Campagne M, Beres T, Friesenhahn M, Zhang Y, et al. A phase Ia dose-escalation study of the anti-factor D monoclonal antibody fragment FCFD4514S in patients with geographic atrophy. Retina 2014; 34:313-320.
36. Roche presents lampalizumab biomarker data from phase II study in advanced form of dry macular degeneration. http://www.roche.com/investors/ir-update/inv-update-2013-11-16.htm.
37. Roche's lampalizumab phase II data shows benefit in patients with the advanced form of dry age-related macular degeneration. http://www.roche.com/investors/ir-update/inv-update-⁣ 2013-08-27.htm.
38. Khandhadia S, Cipriani V, Yates JRW, Lotery AJ: Age-related macular degeneration and the complement system. Immunobiology 2012; 217:127-146.
39. A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA). US National Institutes of Health, 2014, https://clinicaltrials.gov/ct2/show/NCT02247479 (accessed July 17, 2015).